Molecular Partners (MOLN) News Today → He cracked the code to crypto… (From Weiss Ratings) (Ad) Free MOLN Stock Alerts $3.71 +0.16 (+4.51%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 9, 2024 | marketbeat.comTrading was temporarily halted for "MOLN" at 09:05 AM with a stated reason of "LULD pause."May 1, 2024 | seekingalpha.comMOLN Molecular Partners AGApril 29, 2024 | finance.yahoo.comMolecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of ActionApril 29, 2024 | globenewswire.comMolecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of ActionApril 19, 2024 | globenewswire.comLife Science Cares Launches in SwitzerlandApril 18, 2024 | finance.yahoo.comWe Think Molecular Partners (VTX:MOLN) Needs To Drive Business Growth CarefullyApril 17, 2024 | globenewswire.comMolecular Partners Announces All Board Proposals Approved at the Annual General MeetingApril 12, 2024 | marketbeat.comTrading was temporarily halted for "MOLN" at 03:04 PM with a stated reason of "LULD pause."April 12, 2024 | marketbeat.comTrading was temporarily halted for "MOLN" at 02:04 PM with a stated reason of "LULD pause."April 4, 2024 | bizjournals.comBeyond Benign, MilliporeSigma partner on green chemistryApril 3, 2024 | marketbeat.comTrading was temporarily halted for "MOLN" at 09:04 AM with a stated reason of "LULD pause."March 26, 2024 | globenewswire.comMolecular Partners Publishes Invitation to Annual General Meeting 2024March 21, 2024 | markets.businessinsider.comLeerink Partners Keeps Their Hold Rating on Molecular Partners (MOLN)March 14, 2024 | globenewswire.comMolecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023March 13, 2024 | markets.businessinsider.comMolecular Partners AG (spons. ADRs) hosts conference call for investorsMarch 13, 2024 | finance.yahoo.comThe past three years for Molecular Partners (VTX:MOLN) investors has not been profitableMarch 2, 2024 | uk.investing.comMolecular Partners wins dismissal of securities lawsuitMarch 1, 2024 | globenewswire.comMolecular Partners Announces Dismissal of Class Action LawsuitMarch 1, 2024 | globenewswire.comMolecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor PresentationsJanuary 7, 2024 | finance.yahoo.comMolecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare ConferenceJanuary 5, 2024 | msn.comMolecular Partners, Orano to collaborate on RDT therapies for cancerJanuary 3, 2024 | marketbeat.comTrading was temporarily halted for "MOLN" at 11:01 AM with a stated reason of "LULD pause."December 31, 2023 | ca.finance.yahoo.comMolecular Partners AG (6ML0.MU)December 29, 2023 | marketbeat.comMolecular Partners AG (NASDAQ:MOLN) Short Interest Down 39.2% in DecemberMolecular Partners AG (NASDAQ:MOLN - Get Free Report) was the recipient of a large decrease in short interest during the month of December. As of December 15th, there was short interest totalling 6,200 shares, a decrease of 39.2% from the November 30th total of 10,200 shares. Based on an average daily trading volume, of 2,600 shares, the days-to-cover ratio is currently 2.4 days.December 10, 2023 | finance.yahoo.comMolecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual MeetingNovember 11, 2023 | morningstar.comMolecular Partners AG ADR MOLNNovember 2, 2023 | finance.yahoo.comMolecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and ExpositionNovember 1, 2023 | finance.yahoo.comMolecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation SummitOctober 5, 2023 | finance.yahoo.comShareholders in Molecular Partners (VTX:MOLN) are in the red if they invested five years agoAugust 24, 2023 | finance.yahoo.comMolecular Partners Reports H1 2023 Corporate Highlights and FinancialsJuly 13, 2023 | finance.yahoo.comOwning 32% shares,hedge funds owners seem interested in Molecular Partners AG (VTX:MOLN),June 27, 2023 | finance.yahoo.comMolecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023June 27, 2023 | finance.yahoo.comMolecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023June 19, 2023 | finance.yahoo.comMolecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation SummitJune 2, 2023 | finance.yahoo.comCompanies Like Molecular Partners (VTX:MOLN) Are In A Position To Invest In GrowthMay 25, 2023 | finance.yahoo.comMolecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 ASCO Annual MeetingMay 15, 2023 | markets.businessinsider.comSVB Securities Sticks to Their Hold Rating for Molecular Partners (MOLN)May 1, 2023 | marketbeat.comMolecular Partners AG (NASDAQ:MOLN) Short Interest UpdateMolecular Partners AG (NASDAQ:MOLN - Get Rating) was the recipient of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 22,500 shares, a growth of 9.2% from the March 31st total of 20,600 shares. Based on an average daily volume of 2,200 shares, the short-interest ratio is presently 10.2 days.April 15, 2023 | marketwatch.comMolecular Partners to Present Additional Preclinical Data Supporting the Company's Radio DARPin Therapy Platform at AACRApril 14, 2023 | finance.yahoo.comMolecular Partners to Present Additional Preclinical Data Supporting the Company’s Radio DARPin Therapy Platform at AACRMarch 13, 2023 | finance.yahoo.comMolecular Partners AG (NASDAQ:MOLN) Q4 2022 Earnings Call TranscriptMarch 9, 2023 | msn.comMolecular Partners GAAP EPS of $3.54 misses by $0.52, revenue of $189.6M misses by $5.3MMarch 9, 2023 | finance.yahoo.comMolecular Partners Reports Corporate Highlights From Q4 2022 and Key Financials for Full Year 2022March 7, 2023 | marketbeat.comPotential Earnings Have Rated Ambrx Biopharma a Moderate Buy (MOLN)Ambrx Pharmaceuticals, Inc. could see positive earnings next year. And while share value could go down, analysts thin rate AMAM a Moderate BuyFebruary 22, 2023 | markets.businessinsider.comSVB Securities Keeps Their Hold Rating on Molecular Partners (MOLN)February 3, 2023 | marketbeat.comAlphaCentric Advisors LLC Purchases Shares of 32,500 Molecular Partners AG (NASDAQ:MOLN)AlphaCentric Advisors LLC purchased a new stake in Molecular Partners AG (NASDAQ:MOLN - Get Rating) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 32,500 shares of the company's stock, valued at approximately $218,000. AlpJanuary 16, 2023 | finance.yahoo.comMolecular Partners Initiates Clinical Study of Trispecific Candidate MP0533 for the Treatment of Acute Myeloid LeukemiaJanuary 12, 2023 | finance.yahoo.comHedge funds own 28% of Molecular Partners AG (VTX:MOLN) shares but individual investors control 41% of the companyJanuary 8, 2023 | finance.yahoo.comMolecular Partners Provides Updates at 41st Annual JPM Healthcare ConferenceDecember 30, 2022 | finance.yahoo.comMolecular Partners to Present at 41st Annual JP Morgan Healthcare Conference and Swiss Investor Conferences Get Molecular Partners News Delivered to You Automatically Sign up to receive the latest news and ratings for MOLN and its competitors with MarketBeat's FREE daily newsletter. Email Address Gold Set to EXPLODE! (Ad)Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025. Click here now to download the free Precious Metals Buying Guide! MOLN Media Mentions By Week MOLN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MOLN News Sentiment▼0.930.55▲Average Medical News Sentiment MOLN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MOLN Articles This Week▼20▲MOLN Articles Average Week Get Molecular Partners News Delivered to You Automatically Sign up to receive the latest news and ratings for MOLN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Vaxart News Today Cardiol Therapeutics News Today DBV Technologies News Today Karyopharm Therapeutics News Today Scilex News Today Vigil Neuroscience News Today Omega Therapeutics News Today Cardiff Oncology News Today aTyr Pharma News Today BioAtla News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MOLN) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks News[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap Sniper Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Molecular Partners AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
